The research provides an evolving picture of the vaccine’s performance in children, and some experts said it suggested a need to consider increasing the size of the dose 5- to 11-year-olds receive.
Pfizer-BioNTech vaccine effectiveness wanes for children 5 to 11, but still protects against serious outcomes, CDC data show
